Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia
Standard
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia : results of a meta-analysis. / Eichhorst, Barbara F; Fischer, Kirsten; Fink, Anna-Maria; Elter, Thomas; Wendtner, Clemens M; Goede, Valentin; Bergmann, Manuela; Stilgenbauer, Stephan; Hopfinger, Georg; Ritgen, Matthias; Bahlo, Jasmin; Busch, Raymonde; Hallek, Michael; German CLL Study Group (GCLLSG) ; Bokemeyer, Carsten.
In: BLOOD, Vol. 117, No. 6, 10.02.2011, p. 1817-21.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia
T2 - results of a meta-analysis
AU - Eichhorst, Barbara F
AU - Fischer, Kirsten
AU - Fink, Anna-Maria
AU - Elter, Thomas
AU - Wendtner, Clemens M
AU - Goede, Valentin
AU - Bergmann, Manuela
AU - Stilgenbauer, Stephan
AU - Hopfinger, Georg
AU - Ritgen, Matthias
AU - Bahlo, Jasmin
AU - Busch, Raymonde
AU - Hallek, Michael
AU - German CLL Study Group (GCLLSG)
AU - Bokemeyer, Carsten
PY - 2011/2/10
Y1 - 2011/2/10
N2 - The clinical value of imaging is well established for the follow-up of many lymphoid malignancies but not for chronic lymphocytic leukemia (CLL). A meta-analysis was performed with the dataset of 3 German CLL Study Group phase 3 trials (CLL4, CLL5, and CLL8) that included 1372 patients receiving first-line therapy for CLL. Response as well as progression during follow-up was reassessed according to the National Cancer Institute Working Group1996 criteria. A total of 481 events were counted as progressive disease during treatment or follow-up. Of these, 372 progressions (77%) were detected by clinical symptoms or blood counts. Computed tomography (CT) scans or ultrasound were relevant in 44 and 29 cases (9% and 6%), respectively. The decision for relapse treatment was determined by CT scan or ultrasound results in only 2 of 176 patients (1%). CT scan results had an impact on the prognosis of patients in complete remission only after the administration of conventional chemotherapy but not after chemoimmunotherapy. In conclusion, physical examination and blood count remain the methods of choice for staging and clinical follow-up of patients with CLL as recommended by the International Workshop on Chronic Lymphocytic Leukemia 2008 guidelines. These trials are registered at http://www.isrctn.org as ISRCTN 75653261 and ISRCTN 36294212 and at http://www.clinicaltrials.gov as NCT00281918.
AB - The clinical value of imaging is well established for the follow-up of many lymphoid malignancies but not for chronic lymphocytic leukemia (CLL). A meta-analysis was performed with the dataset of 3 German CLL Study Group phase 3 trials (CLL4, CLL5, and CLL8) that included 1372 patients receiving first-line therapy for CLL. Response as well as progression during follow-up was reassessed according to the National Cancer Institute Working Group1996 criteria. A total of 481 events were counted as progressive disease during treatment or follow-up. Of these, 372 progressions (77%) were detected by clinical symptoms or blood counts. Computed tomography (CT) scans or ultrasound were relevant in 44 and 29 cases (9% and 6%), respectively. The decision for relapse treatment was determined by CT scan or ultrasound results in only 2 of 176 patients (1%). CT scan results had an impact on the prognosis of patients in complete remission only after the administration of conventional chemotherapy but not after chemoimmunotherapy. In conclusion, physical examination and blood count remain the methods of choice for staging and clinical follow-up of patients with CLL as recommended by the International Workshop on Chronic Lymphocytic Leukemia 2008 guidelines. These trials are registered at http://www.isrctn.org as ISRCTN 75653261 and ISRCTN 36294212 and at http://www.clinicaltrials.gov as NCT00281918.
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Blood Cell Count
KW - Disease Progression
KW - Disease-Free Survival
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Leukemia, Lymphocytic, Chronic, B-Cell
KW - Male
KW - Middle Aged
KW - Prognosis
KW - Recurrence
KW - Remission Induction
KW - Tomography, X-Ray Computed
U2 - 10.1182/blood-2010-04-282228
DO - 10.1182/blood-2010-04-282228
M3 - SCORING: Journal article
C2 - 21139079
VL - 117
SP - 1817
EP - 1821
JO - BLOOD
JF - BLOOD
SN - 0006-4971
IS - 6
ER -